Skip to main content
Top of the Page

What Is the Benefit of Blinatumomab in MRD-Positive B-Cell ALL?

By Melissa Badamo - Last Updated: February 23, 2024

Blinatumomab may offer a benefit in reducing the risk of relapse for adult patients with B-cell acute lymphoblastic leukemia (ALL) with low levels of measurable residual disease (MRD) detected by clonoSEQ, according to a study presented at the 2024 Tandem Transplant & Cellular Therapy Meetings of ASTCT® and CIBMTR®.

“In B-cell ALL, blinatumomab may offer a [cumulative incidence of relapse (CIR)] benefit to patients with low levels of MRD detected on clonoSEQ,” reported Anush Ginosyan, MD, of the University of Southern California’s Keck School of Medicine, and colleagues.

The study included 47 adult patients (median age, 45) with B-cell ALL treated at the Norris Comprehensive Cancer Center between 2016 and 2022 who received blinatumomab for MRD positivity tracked using clonoSEQ. Twenty-six patients were treated with blinatumomab for MRD positivity. Patients who did not receive blinatumomab were also included if they were MRD positive with clonoSEQ.

The three-year overall survival (OS), disease-free survival (DFS), and CIR were 95.4% (95% CI, 89.3-100%), 75.1% (95% CI, 60.4-93.5%), and 20.3% (95% CI, 7.2-38.0%), respectively. 

Fourteen patients (53.8%) treated with blinatumomab achieved MRD negativity within a median time of 3.1 months. Of 31 patients with low MRD levels (<0.1%), blinatumomab did not improve DFS (HR=0.41; 95% CI, 0.04-3.91; P=0.44).

There were no relapses or death in patients treated with blinatumomab who achieved MRD negativity. However, two relapses and one death occurred among patients who did not respond to treatment.



Ginosyan AA, Ashouri K, Hom BM, et al. Blinatumomab therapy for low level minimal residual disease detected by next-generation sequencing in adult B-cell acute lymphoblastic leukemia. Abstract #133. Presented at the 2024 Tandem Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®; February 21-24, 2024; San Antonio, Texas.

Original Source: What Is the Benefit of Blinatumomab in MRD-Positive B-Cell ALL? | Blood Cancers Today


Back to Top